Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary
3.1. Snippet by Immune Checkpoint Inhibitors Type
3.2. Snippet by Disease Type
3.3. Snippet by Region

4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing collaborations and regulatory approvals for various indications
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Life-threatening complications associated with the checkpoint inhibitors
4.1.3. Opportunity
4.1.4. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion

6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Immune Checkpoint Inhibitors Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immune Checkpoint Inhibitors Type
7.1.2. Market Attractiveness Index, By Immune Checkpoint Inhibitors Type
7.2. PD-1 Inhibitors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. PDL-1 Inhibitors
7.4. CTLA-4 Inhibitor

8. By Disease Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Metastatic Melanoma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Recombinant Human NGF Eye Drops
8.2.4. Serum-Derived Eye Drops
8.3. Non-Small Lung Cancer
8.4. Head and Neck Cancers
8.5. Hodgkin Lymphoma
8.6. Others

9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immune Checkpoint Inhibitors Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immune Checkpoint Inhibitors Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immune Checkpoint Inhibitors Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immune Checkpoint Inhibitors Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immune Checkpoint Inhibitors Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles
11.1. Bristol Myers Squibb*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Merck & Co., Inc.
11.3. Genentech USA, Inc.
11.4. AstraZeneca
11.5. Regeneron Pharmaceuticals, Inc.
11.6. GSK plc
11.7. Novartis AG
11.8. Pfizer, Inc.
11.9. Janssen Global Services, LLC
11.10. Incyte
LIST NOT EXHAUSTIVE

12. Appendix
12.1. About Us and Services
12.2. Contact Us